Johnson & Johnson (NYSE:JNJ) Stock Holdings Trimmed by Financial Security Advisor Inc.

Financial Security Advisor Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 0.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,222 shares of the company’s stock after selling 215 shares during the quarter. Johnson & Johnson comprises approximately 1.8% of Financial Security Advisor Inc.’s portfolio, making the stock its 10th largest holding. Financial Security Advisor Inc.’s holdings in Johnson & Johnson were worth $7,329,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Catalina Capital Group LLC raised its position in shares of Johnson & Johnson by 22.2% during the 3rd quarter. Catalina Capital Group LLC now owns 8,098 shares of the company’s stock valued at $1,312,000 after buying an additional 1,473 shares during the period. Avidian Wealth Enterprises LLC raised its position in shares of Johnson & Johnson by 2.8% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 16,749 shares of the company’s stock valued at $2,714,000 after buying an additional 452 shares during the period. Beacon Financial Advisory LLC raised its position in shares of Johnson & Johnson by 1.4% during the 3rd quarter. Beacon Financial Advisory LLC now owns 8,438 shares of the company’s stock valued at $1,367,000 after buying an additional 116 shares during the period. Balentine LLC raised its position in shares of Johnson & Johnson by 76.0% during the 3rd quarter. Balentine LLC now owns 7,748 shares of the company’s stock valued at $1,256,000 after buying an additional 3,345 shares during the period. Finally, Tobias Financial Advisors Inc. raised its position in shares of Johnson & Johnson by 2.0% during the 3rd quarter. Tobias Financial Advisors Inc. now owns 4,529 shares of the company’s stock valued at $734,000 after buying an additional 87 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $157.76 on Thursday. The business has a 50 day moving average price of $162.96 and a 200 day moving average price of $155.76. The stock has a market cap of $379.83 billion, a price-to-earnings ratio of 22.83, a PEG ratio of 2.81 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. TD Securities dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Citigroup lifted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.